Guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Published guidance on this topic (8)
- New guidance in the last 6 months (1)
- Updated guidance in the last 6 months (0)
- In development guidance (7)
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (1)
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Quality standards
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (1)
- New quality standards in the last 6 months (1)
- Updated quality standards in the last 6 months (0)
- In development quality standards (1)
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Guidance by programme
-
NICE guidelines (2)
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance (8)
Review clinical and cost effectiveness of new treatments.
-
Interventional procedures guidance (5)
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Advice by programme
-
Medtech innovation briefings (1)
Review the evidence and likely costs of medical devices and technologies.
Products being developed or updated
-
In development (8)
Guidance, quality standards and advice being developed.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE guidelines
Review the evidence across broad health and social care topics.
-
Pancreatic cancer in adults: diagnosis and management (NG85)
-
Suspected cancer: recognition and referral (NG12)
Quality standards
Set out priority areas for quality improvement in health and social care.
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
-
Irreversible electroporation for treating pancreatic cancer (IPG579)
-
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)
-
Laparoscopic distal pancreatectomy (IPG204)
Medtech innovation briefings
Review the evidence and likely costs of medical devices and technologies.
In development
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
-
Pancreatic cancer
-
Pancreatic cancer - capecitabine [ID389]
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
New guidance and advice
Guidance and advice added since April 2018
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: